Abstract 74P
Background
ERBB2, a receptor tyrosine kinase, is commonly affected by mutations, amplifications, and overexpression in various types of cancers. Drugs targeting ERBB2 are gradually being promoted to various types of cancer. However, the variation of ERBB2 in Chinese population and the relationship between ERBB2 high expression abnormalities and the tumor immune microenvironment remains unclear.
Methods
We utilized genomic data from over 10,000 pan-cancer Chinese populations in CbioPortal to detect somatic mutations and copy number variations. We also performed RNA sequencing date in TCGA (pan-cancer Atlas studies) to determine ERBB2 expression in diverse cancer types and evaluate the immune gene characteristics and content of tumor-infiltrating immune cell populations.
Results
A total of 309 ERBB2 amplifications, 169 ERBB2 substitution or insertion deletions, and 28 ERBB2 fusions or rearrangements were detected in 10,194 patients. The ERBB2 amplification rate of breast cancer (23.84%), gallbladder cancer (13.75%) and urothelium cancer (8.33%) ranked the top three among all cancer types. Among the co-mutated genes with ERBB2 mutations, TP53 (68.8%), CDK12 (34.7%), and RARA (18.7%) have the highest proportion of mutations. Furthermore, among 10,967 RNA datasets in TCGA, breast cancer, esophageal squamous cell carcinoma, and gastric adenocarcinoma displayed the highest average expression levels of ERBB2. Patients with high ERBB2 expression exhibited similar TMB values to those with low ERBB2 expression. However, in breast cancer, colon cancer, lung adenocarcinoma and lung squamous carcinoma, ERBB2 high expression was significantly associated with a higher proportion of activated mast cells, monocytes, and regulatory T cells, while the percentage of resting mast cells and M1 macrophages was notably lower.
Conclusions
Our study identified ERBB2 variation patterns among a cohort of Chinese solid tumor patients and demonstrated that ERBB2 abnormality high expression is associated with an activated immune system and a stronger inflammatory response. Our findings offer insights into the potential benefits of using immune checkpoint inhibitors for this type of patient.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
14P - Peripheral immune kinetics in survival prediction of small cell lung cancer patients treated with immune checkpoint blockade therapy
Presenter: MIGUEL GALINDO CAMPOS
Session: Poster session 09
15P - CBL E3 ubiquitin ligases are key inhibitory regulators in PD-1/LAG-3 co-signaling in human cancers, targeted through bispecific co-blockade
Presenter: Luisa Chocarro
Session: Poster session 09
16P - Terminally exhausted CD8+ T cells and increased immunosuppressive soluble factors in malignant ascites of patients with gastric cancer with peritoneal metastasis
Presenter: Hye Sook Han
Session: Poster session 09
17P - Continued expansion of long-lived effect CD8+ T cells associates with durable response post-PD-1 blockade
Presenter: Robert Watson
Session: Poster session 09
18P - Exposure of calreticulin is required for vitamin C immunomediated cancer surveillance
Presenter: Alessandro Cavaliere
Session: Poster session 09
19P - Preclinical and clinical significance of VEGF deprivation in ovarian cancer through a specific active immunotherapy
Presenter: Yanelys Morera
Session: Poster session 09
20P - The essential role of DNA repair in the pharmacological activities of AST-3424
Presenter: Fanying Meng
Session: Poster session 09
21P - Implications of KMT2C knockdown for DNA damage repair in breast cancer
Presenter: Philip Bredin
Session: Poster session 09
22P - Clinical significance of DNA damage response mutations in early stage NSCLC
Presenter: Haoran Zhang
Session: Poster session 09
23P - PMC-309: A highly selective anti-VISTA antibody reverses immunosuppressive TME to immune-supportive
Presenter: Cheon Ho Park
Session: Poster session 09